 N01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of Brivaracetam BRV; as well as the effect of BRV on subjects health-related quality of life and to explore the direct medical resource use for BRV for subjects entering N01372 from a study where pharmacoeconomic data was collected. BRV will be used at doses up to maximum of 200 mgday, as adjunctive treatment in subjects aged 16 years or older with Epilepsy. 